Biofrontera Inc. Warrants (BFRIW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BFRIW SEC filings page.
Biofrontera Inc. Warrants (BFRIW) reported $46.2M in revenue over the twelve months to Jun 30, 2026, up 17.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Biofrontera is narrowing operating losses as sales grow, but its operations still require outside financing to fund cash needs.
Revenue increased11.7% in FY2025 while free-cash-flow margin fell4.5 pp , indicating that narrower reported losses did not translate into better cash conversion.
The balance sheet became less liability-heavy: liabilities fell to
SG&A remained
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 4 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Biofrontera Inc. Warrants's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Biofrontera Inc. Warrants, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Biofrontera Inc. Warrants had 12M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Biofrontera Inc. Warrants scores 20/100 among other emerging companies.
Biofrontera Inc. Warrants spent $3.7M on research and development in fiscal year 2025, which was 7.0% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Biofrontera Inc. Warrants scores 30/100 among other emerging companies.
Biofrontera Inc. Warrants reported revenue of $41.7M in fiscal year 2025, against $37.3M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Biofrontera Inc. Warrants scores 56/100 among other emerging companies.
Biofrontera Inc. Warrants's operations used $13.4M of cash in fiscal year 2025, against $10.3M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Biofrontera Inc. Warrants scores 73/100 among other emerging companies.
Not available for Biofrontera Inc. Warrants, so it is left out of the overall score, which averages the 4 of 6 dimensions that can be computed.
Biofrontera Inc. Warrants passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), the one computable operating efficiency signal (asset turnover improving) does not pass.
Biofrontera Inc. Warrants reported a net loss of $10.5M while operations used $13.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Biofrontera Inc. Warrants reported an operating loss of $11.3M against $452K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Biofrontera Inc. Warrants generated $12.0M in revenue in Q2 2026. This represents an increase of 32.9% from the same quarter a year earlier. Against the prior quarter it is up 19.0%.
Biofrontera Inc. Warrants's EBITDA was -$524K in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Biofrontera Inc. Warrants reported a net loss of $604K in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Biofrontera Inc. Warrants earned -$0.05 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Cash & Balance Sheet
Biofrontera Inc. Warrants recorded an outflow of $1.7M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Biofrontera Inc. Warrants held $4.7M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
Biofrontera Inc. Warrants's operating margin was -4.4% in Q2 2026, reflecting core business profitability. This is up 51.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 38.5 percentage points.
Biofrontera Inc. Warrants's net profit margin was -5.0% in Q2 2026, showing the share of revenue converted to profit. This is up 53.9 percentage points from the same quarter a year earlier. Against the prior quarter it is up 42.1 percentage points.
Biofrontera Inc. Warrants's quarterly ROE was -10.1% in Q2 2026: one quarter's net income over shareholder equity, not annualized. Against the prior quarter it is up 68.2 percentage points.
Not reported for Q2 2026.
Capital Allocation
Biofrontera Inc. Warrants invested $448K in research and development in Q2 2026. This represents a decrease of 48.5% from the same quarter a year earlier. Against the prior quarter it is down 50.2%.
Biofrontera Inc. Warrants reported no capital expenditure in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Not reported for Q2 2026.
BFRIW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $12.0M+32.9% | $10.1M+17.4% | $17.1M+36.2% | $7.0M-22.5% | $9.0M+15.2% | $8.6M+8.5% | $12.6M+18.5% | $9.0M+1.3% |
| R&D Expenses | $448K-48.5% | $900K-25.4% | $788K+0.8% | $854K+27.7% | $870K+40.1% | $1.2M+7000.0% | $782K | $669K+1927.3% |
| SG&A Expenses | $9.6M-8.5% | $11.0M+27.1% | $8.5M+3.9% | $10.0M+19.3% | $10.5M+33.0% | $8.7M-6.5% | $8.2M-9.9% | $8.4M-2.3% |
| Operating Income | -$524Kn/m | -$4.3Mn/m | $4.6Mn/m | -$6.3Mn/m | -$5.1Mn/m | -$4.5Mn/m | -$1.7Mn/m | -$5.0Mn/m |
| EBITDA | -$524Kn/m | -$4.3Mn/m | N/A | N/A | -$5.1Mn/m | -$4.5Mn/m | -$1.7Mn/m | -$4.8Mn/m |
| Interest Expense | $126K+9.6% | $125K+4.2% | $106K | $111K | $115K-81.5% | $120K-91.6% | N/A | N/A |
| Income Tax | $23K+9.5% | N/A | -$1Kn/m | $6K+100.0% | $21K+5.0% | -$1K-200.0% | -$2Kn/m | $3K+200.0% |
| Net Income | -$604Kn/m | -$4.8Mn/m | $5.6Mn/m | -$6.6Mn/m | -$5.3Mn/m | -$4.2Mn/m | -$1.4M-139.6% | -$5.7Mn/m |
| EPS (Basic) | -$0.05n/m | -$0.41n/m | $0.63+270.6% | -$0.62 | -$0.57 | -$0.47 | $0.17-96.3% | -$0.98 |
| EPS (Diluted) | -$0.05n/m | -$0.41n/m | $0.63+270.6% | -$0.62 | -$0.57 | -$0.47 | $0.17-96.3% | -$0.98 |
| Diluted Shares (Avg) | 13M+38.2% | 12M+31.7% | N/A | 11M | 9M | 9M | N/A | 6M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
BFRIW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $24.1M+19.5% | $24.8M+49.4% | $28.6M+29.2% | $15.4M-16.7% | $20.1M-6.6% | $16.6M-32.5% | $22.1M-20.9% | $18.5M-45.7% |
| Current Assets | $12.4M-33.9% | $13.2M-14.2% | $18.1M-12.6% | $14.4M-14.9% | $18.8M+7.7% | $15.3M-23.9% | $20.7M-10.3% | $16.9M-42.8% |
| Cash & Equivalents | $4.7M-35.6% | $6.3M+253.9% | $6.4M+8.2% | $3.4M+18.9% | $7.2M+65.3% | $1.8M-53.2% | $5.9M+339.7% | $2.9M-16.0% |
| Short-Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m |
| Inventory | $1.1M-72.8% | $1.2M-81.1% | $1.4M-78.5% | $4.3M-33.7% | $4.0M+2.1% | $6.5M-5.5% | $6.6M-39.1% | $6.5M-59.4% |
| Accounts Receivable | $5.5M+40.2% | $3.9M-3.8% | $7.3M+37.2% | $3.0M-38.6% | $4.0M+12.9% | $4.0M+14.5% | $5.3M+3.0% | $4.9M+28.5% |
| Long-Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0n/m |
| Total Liabilities | $18.1M-27.0% | $18.7M+16.1% | $18.1M+2.4% | $18.0M+38.6% | $24.8M+132.7% | $16.1M-39.0% | $17.7M-23.6% | $13.0M-60.7% |
| Current Liabilities | $10.5M-46.5% | $10.9M-0.3% | $11.9M-1.0% | $12.6M+13.8% | $19.7M+112.4% | $11.0M-21.9% | $12.0M-33.5% | $11.0M-62.1% |
| Non-Current Liabilities | $7.6M+47.7% | $7.8M+51.0% | $6.2M+9.6% | $5.4M+178.6% | $5.1M+267.2% | $5.2M-58.3% | $5.6M+11.8% | $2.0M-50.4% |
| Total Equity | $6.0Mn/m | $6.1M+1194.2% | $10.5M+136.4% | -$2.6M-146.7% | -$4.7M-142.8% | $469Kn/m | $4.4M-7.5% | $5.5M+432.8% |
| Retained Earnings | -$133.3Mn/m | -$132.7Mn/m | -$127.9Mn/m | -$133.6Mn/m | -$126.9Mn/m | -$121.6Mn/m | -$117.4Mn/m | -$116.0Mn/m |
Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.
BFRIW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$1.7Mn/m | -$70Kn/m | -$2.4Mn/m | -$3.8Mn/m | -$3.0Mn/m | -$4.1Mn/m | -$1.0Mn/m | -$1.2Mn/m |
| Depreciation & Amortization | $0-100.0% | $55K+89.7% | N/A | N/A | $4K-96.7% | $29K-77.3% | $43K-81.3% | $129K+6.6% |
| Stock-Based Compensation | N/A | $342K+43.1% | N/A | N/A | N/A | $239K+4.8% | N/A | N/A |
| Capital Expenditures | $0-100.0% | $5K+66.7% | -$1K0.0% | -$1Kn/m | $1K-97.9% | $3K-94.7% | $1K-88.9% | $0n/m |
| Free Cash Flow | -$1.7Mn/m | -$75Kn/m | -$2.4Mn/m | -$3.8Mn/m | -$3.0Mn/m | -$4.1Mn/m | -$1.0Mn/m | -$1.2Mn/m |
| Investing Cash Flow | $0n/m | -$5Kn/m | $3.0Mn/m | $1Kn/m | -$1K | -$3K | -$1K-101.4% | $0-100.0% |
| Financing Cash Flow | N/A | N/A | $2.4M-42.0% | $0n/m | N/A | N/A | $4.0M-39.7% | -$298K-150.4% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
BFRIW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | -4.4%+51.9pp | -42.8%+10.1pp | 26.6%+40.3pp | -89.8%-34.8pp | -56.3%+8.4pp | -52.9%+16.1pp | -13.6%+22.9pp | -55.0%-3.1pp |
| Net Margin | -5.0%+53.9pp | -47.1%+1.8pp | 33.0%+44.1pp | -95.2%-32.2pp | -59.0%-55.7pp | -48.9% | -11.1%-44.4pp | -62.9%+8.4pp |
| Return on Equity | -10.1% | -78.3%+817.9pp | 53.8%+85.3pp | N/A | N/A | -896.2% | -31.5%-105.1pp | -102.5%+508.5pp |
| Return on Assets | -2.5%+23.9pp | -19.2%+6.2pp | 19.8%+26.1pp | -43.1%-12.5pp | -26.4%-25.2pp | -25.3%+17.1pp | -6.3%-18.9pp | -30.6%-12.0pp |
| Current Ratio | 1.18+0.2x | 1.20-0.2x | 1.52-0.2x | 1.15-0.4x | 0.96-0.9x | 1.400.0x | 1.72+0.4x | 1.53+0.5x |
| Liabilities-to-Equity | 3.04 | 3.08-31.3x | 1.73-2.3x | N/A | N/A | 34.37 | 3.99-0.8x | 2.35-29.5x |
| Asset Turnover | 0.50+0.1x | 0.41-0.1x | 0.600.0x | 0.450.0x | 0.45+0.1x | 0.52+0.2x | 0.57+0.2x | 0.49+0.2x |
| FCF Margin | -13.8%+19.9pp | -0.7%+47.2pp | -13.9%-5.8pp | -54.7%-41.3pp | -33.7%+27.1pp | -48.0%-5.2pp | -8.1%+75.7pp | -13.4%+9.1pp |
Not reported in any period shown, so not listed: Gross Margin, Debt-to-Equity.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Biofrontera Inc. Warrants BFRIW | FY2025 | $41.7M | -$10.5M | -25.3% | N/A | 45/100 |
| Biofrontera Inc. BFRI | FY2025 | $41.7M | -$10.5M | -25.3% | $11.6M | 45/100 |
| Sunshine Biopharma Inc. SBFM | FY2025 | $36.3M | -$6.0M | -16.5% | $2.5M | 60/100 |
| Sunshine Biopharma Inc. warrant SBFMW | FY2025 | $36.3M | -$6.0M | -16.5% | N/A | 60/100 |
| Incannex Healthcare Limited IXHL | FY2026 | $0 | -$19.3M | N/A | $32.6M | — |
Where Biofrontera Inc. Warrants Ranks
Frequently Asked Questions
What is Biofrontera Inc. Warrants's annual revenue?
Biofrontera Inc. Warrants (BFRIW) reported $41.7M in total revenue for fiscal year 2025. This represents a 11.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Biofrontera Inc. Warrants's revenue growing?
Biofrontera Inc. Warrants (BFRIW) revenue grew by 11.7% year-over-year, from $37.3M to $41.7M in fiscal year 2025.
Is Biofrontera Inc. Warrants profitable?
No, Biofrontera Inc. Warrants (BFRIW) reported a net loss of $6.4M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $10.5M, with a net profit margin of -25.3%.
What is Biofrontera Inc. Warrants's EBITDA?
Biofrontera Inc. Warrants (BFRIW) had EBITDA of -$11.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Biofrontera Inc. Warrants's operating margin?
Biofrontera Inc. Warrants (BFRIW) had an operating margin of -27.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Biofrontera Inc. Warrants's net profit margin?
Biofrontera Inc. Warrants (BFRIW) had a net profit margin of -25.3% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Biofrontera Inc. Warrants's return on equity (ROE)?
Biofrontera Inc. Warrants (BFRIW) has a return on equity of -100.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Biofrontera Inc. Warrants's free cash flow?
Biofrontera Inc. Warrants (BFRIW) recorded an outflow of $13.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Biofrontera Inc. Warrants's operating cash flow?
Biofrontera Inc. Warrants (BFRIW) recorded an outflow of $13.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Biofrontera Inc. Warrants's total assets?
Biofrontera Inc. Warrants (BFRIW) had $28.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Biofrontera Inc. Warrants's capital expenditures?
Biofrontera Inc. Warrants (BFRIW) invested $2K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Biofrontera Inc. Warrants spend on research and development?
Biofrontera Inc. Warrants (BFRIW) invested $3.7M in research and development during fiscal year 2025.
What is Biofrontera Inc. Warrants's current ratio?
Biofrontera Inc. Warrants (BFRIW) had a current ratio of 1.52 as of fiscal year 2025, which is generally considered healthy.
What is Biofrontera Inc. Warrants's liabilities-to-equity ratio?
Biofrontera Inc. Warrants (BFRIW) had a liabilities-to-equity ratio of 1.73 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Biofrontera Inc. Warrants's return on assets (ROA)?
Biofrontera Inc. Warrants (BFRIW) had a return on assets of -36.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Biofrontera Inc. Warrants's Piotroski F-Score?
Biofrontera Inc. Warrants (BFRIW) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Biofrontera Inc. Warrants's earnings high quality?
Biofrontera Inc. Warrants (BFRIW) reported a net loss of $10.5M while operations used $13.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Biofrontera Inc. Warrants cover its interest payments?
Biofrontera Inc. Warrants (BFRIW) reported an operating loss of $11.3M against $452K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is Biofrontera Inc. Warrants?
Biofrontera Inc. Warrants (BFRIW) scores 45 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Biofrontera Inc. Warrants it averages the 4 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.